metaPreg - TNF-alpha inhibitors during pregnancy

TNF-alpha inhibitors

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.57 [1.16, 2.14]	0%	13 studies	206	971	low	ROB	2.52 [1.58; .]
Major congenital malformations	1.67 [1.08, 2.58]	0%	9 studies	64	680	not evaluable	ROB	2.72 [1.37; .]
Oro-facial clefts	-	-	0 study					-
Respiratory system anomalies	-	-	0 study					-
Atrial septal defect	-	-	0 study					-
Atrioventricular septal defect	-	-	0 study					-
Cardiac septal defects	-	-	0 study					-
Congenital hydronephrosis	-	-	0 study					-
Ear, face and neck anomalies	-	-	0 study					-
Eye defects	-	-	0 study					-
Eye, ear, face and neck malformations	-	-	0 study					-
Hypospadias	-	-	0 study					-
Ventricular septal defect	-	-	0 study					-
8 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.38 [1.16, 1.64]	13%	18 studies	1,455	2,329	low	ROB	2.11 [1.60; .]
Small for gestational age (weight)	1.72 [0.83, 3.58]	0%	8 studies	21	311	not evaluable	ROB	-
Low birth weight (< 2500g)	1.86 [0.66, 5.25]	87%	7 studies	291	752	not evaluable	ROB	-
Macrosomia (> 4000g)	2.97 [0.24, 36.82]	0%	2 studies	1	36	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	2.56 [0.15, 42.43]	95%	2 studies	59	100	not evaluable	ROB	-
Gestational diabetes	1.15 [0.88, 1.49]	0%	2 studies	573	394	not evaluable	ROB	-
Maternal consequences (as a whole)	1.66 [1.40, 1.95]	0%	3 studies	4	1,125	not evaluable	ROB	2.70 [2.16; .]
Preeclampsia	0.53 [0.03, 9.33]	68%	2 studies	11	109	not evaluable	ROB	-
Maternal infections	1.42 [1.24, 1.63]	0%	2 studies	19	1,849	not evaluable	ROB	2.19 [1.78; .]
Abruptio placentae (retroplacental hematoma)	-	-	0 study					-
Assisted deliveries (forceps, vacuum, ...)	-	-	0 study					-
Placenta previa	-	-	0 study					-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal infections	0.90 [0.77, 1.04]	0%	7 studies	96	1,064	not evaluable	ROB	-
Neonatal death (< 28 days of life)	4.47 [0.37, 54.48]	0%	2 studies	1	64	not evaluable	ROB	-
Neonatal medical care	-	-	0 study					-
Low Apgar score (< 7) (at 10 min)	-	-	0 study					-
Low Apgar score (< 7) (at 5 min)	-	-	0 study					-
3 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Child/Infant infections (> 1 year)	-	-	0 study					-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	0.99 [0.66, 1.48]	60%	8 studies	820	1,417	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks)	1.43 [0.68, 3.03]	0%	6 studies	49	1,042	not evaluable	ROB	-
Elective/induced termination of pregnancy	1.65 [1.03, 2.65]	46%	6 studies	509	1,172	not evaluable	ROB	2.68 [1.19; .]
Intrauterine deaths (as a whole or unspecified)	1.57 [0.03, 83.21]	80%	2 studies	9	48	not evaluable	ROB	-
Ectopic pregnancy	12.76 [1.31, 124.74]	0%	2 studies	2	104	not evaluable	ROB	25.02 [1.94; .]
Therapeutic terminations of pregnancy	-	-	0 study					-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders (as a whole)	0.83 [0.29, 2.40]	0%	2 studies	15	96	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study